Krishnamurthi S, Patel Y, Kakkar V V
Thrombosis Research Unit, King's College School of Medicine and Dentistry, Rayne Institute, London, U.K.
Biochim Biophys Acta. 1989 Feb 9;1010(2):258-64. doi: 10.1016/0167-4889(89)90170-5.
The effects of sphingosine, the newly described inhibitor of the enzyme protein kinase C, on human platelet activation, were studied in order to gain further information on the role of protein kinase in platelet responses. Concentrations of the drug (5-20 microM) which had little effect on protein kinase C activation as measured by the phosphorylation of the 45 kDa and 20 kDa protein substrates induced by phorbol 12-myristate 13-acetate (PMA) and thrombin, strongly inhibited platelet aggregation induced by these agonists, as well as aggregation induced by ADP and ionomycin, which caused no detectable protein kinase C activation or 5-hydroxy[14C]tryptamine[( 14C]5HT) secretion. At approx. 10-fold higher concentrations (150-200 microM), sphingosine had significant inhibitory effects on PMA and thrombin-induced 45 kDa and 20 kDa protein phosphorylation. However, at these high concentrations, the drug caused extensive membrane damage/leakiness as suggested by the substantial release of [14C]5HT and [3H]adenine from pre-loaded platelets (50-70% release of both markers), and the total quenching of quin2 fluorescence by Mn2+ in the presence of the drug. Due to the increased membrane leakiness in the presence of the drug, an apparent potentiation of agonist-induced intracellular Ca2+ elevations in quin2-loaded platelets, as well as an increase in quin2 fluorescence with the drug alone (more than 50 microM) were also observed. Despite this, however, thrombin-induced [3H]arachidonate release was severely reduced in the presence of sphingosine, underlining the inhibitory effects at the membrane level. It is concluded that the weak, if any, inhibitory effects on protein kinase C at concentrations not affecting membrane integrity, as well as the inhibitory effects of sphingosine on platelet aggregation, make it an unsuitable compound as a tool for studies on platelet stimulus-response coupling.
为了进一步了解蛋白激酶在血小板反应中的作用,研究了新发现的酶蛋白激酶C抑制剂鞘氨醇对人血小板活化的影响。药物浓度(5 - 20 microM)对佛波醇12 - 肉豆蔻酸酯13 - 乙酸酯(PMA)和凝血酶诱导的45 kDa和20 kDa蛋白底物磷酸化所测定的蛋白激酶C活化影响很小,但能强烈抑制这些激动剂诱导的血小板聚集,以及ADP和离子霉素诱导的聚集,后两者不会引起可检测到的蛋白激酶C活化或5 - 羟色胺[14C]5HT分泌。在大约高10倍的浓度(150 - 200 microM)下,鞘氨醇对PMA和凝血酶诱导的45 kDa和20 kDa蛋白磷酸化有显著抑制作用。然而,在这些高浓度下,药物导致广泛的膜损伤/渗漏,如预加载血小板中[14C]5HT和[3H]腺嘌呤的大量释放(两种标记物均释放50 - 70%)以及药物存在时Mn2+对quin2荧光的完全淬灭所示。由于药物存在时膜渗漏增加,还观察到quin2加载血小板中激动剂诱导的细胞内Ca2+升高明显增强,以及单独使用药物(超过50 microM)时quin2荧光增加。尽管如此,在鞘氨醇存在下,凝血酶诱导的[3H]花生四烯酸释放仍严重减少,突出了其在膜水平的抑制作用。结论是,在不影响膜完整性的浓度下对蛋白激酶C的抑制作用微弱(若有),以及鞘氨醇对血小板聚集的抑制作用,使其成为研究血小板刺激 - 反应偶联的不合适化合物。